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Abstract
Background: Friedreich’s ataxia (FRDA), the most common recessive ataxia in Caucasians, is due to severely reduced levels
of frataxin, a highly conserved protein, that result from a large GAA triplet repeat expansion within the first intron of the
frataxin gene (FXN). Typical marks of heterochromatin are found near the expanded GAA repeat in FRDA patient cells and
mouse models. Histone deacetylase inhibitors (HDACIs) with a pimelic diphenylamide structure and HDAC3 specificity can
decondense the chromatin structure at the FXN gene and restore frataxin levels in cells from FRDA patients and in a GAA
repeat based FRDA mouse model, KIKI, providing an appealing approach for FRDA therapeutics.
Methodology/Principal Findings: In an effort to further improve the pharmacological profile of pimelic diphenylamide
HDACIs as potential therapeutics for FRDA, we synthesized additional compounds with this basic structure and screened
them for HDAC3 specificity. We characterized two of these compounds, 136 and 109, in FRDA patients’ peripheral blood
lymphocytes and in the KIKI mouse model. We tested their ability to upregulate frataxin at a range of concentrations in
order to determine a minimal effective dose. We then determined in both systems the duration of effect of these drugs on
frataxin mRNA and protein, and on total and local histone acetylation. The effects of these compounds exceeded the time of
direct exposure in both systems.
Conclusions/Significance: Our results support the pre-clinical development of a therapeutic approach based on pimelic
diphenylamide HDACIs for FRDA and provide information for the design of future human trials of these drugs, suggesting
an intermittent administration of the drug.
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Introduction
Friedreich’s ataxia (FRDA) is the most common of the early-
onset autosomal recessive ataxias in Caucasians. In addition to
progressive neurological disability, FRDA causes a hypertrophic
cardiomyopathy and an increased risk of diabetes mellitus.
Skeletal abnormalities such as kyphoscoliosis and pes cavus are
common. The first symptoms usually are noticed around the
time of puberty [1,2]. As is the case for almost all neurodegen-
erative diseases, no proven treatment that can stop the
progression of FRDA is now known. FRDA is caused by
severely reduced levels of frataxin [3], a highly conserved
mitochondrial protein, that result from a large GAA triplet
repeat expansion within the first intron of the frataxin gene
(FXN). In vitro and in vivo in bacterial plasmids the expanded
repeat can adopt a triple helical structure that directly interferes
with transcriptional elongation [4]. However, the discovery that
long GAA repeats suppress the expression of a nearby reporter
gene in transgenic mice in a manner similar to position effect
variegation (PEV) observed in Drosophila pointed to a role of
epigenetic mechanisms in the pathogenesis of FRDA [5,6,7].
PEV results in the silencingo fag e n el o c a t e dn e a ra
heterochromatic region because of the spreading of heterochro-
matin into the gene itself. This phenomenon does not occur in
all cells, hence the term ‘‘variegation’’, but nevertheless leads to
an overall downregulation of the involved gene at the tissue and
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of heterochromatin, such as DNA methylation and histone
deacetylation, are found near the expanded GAA repeat both in
FRDA patients’ cells and in mouse models [6,7,8,9]. Based on
these observations, we speculated that histone deacetylase
(HDAC) inhibitors (HDACIs) might reverse FXN silencing by
directly increasing histone acetylation on the FXN gene, leading
to chromatin decondensation and active transcription. The
dynamic interplay between histone acetylation, performed by
histone acetyltransferases (HATs) and deacetylation, catalyzed
by HDACs, is indeed a central mechanism to regulate gene
expression, with increased acetylation associated with an open
chromatin conformation and active genes [10]. Eighteen
HDACs (more strictly, protein deacetylases) have been identi-
fied in the human genome, including the zinc-dependent
HDACs (class I, class II, and class IV), and the NAD
+-
dependent protein deacetylase enzymes (class III, or sirtuins)
[11]. Accordingly, a diverse class of compounds that inhibit
HDACs has been developed. Despite a potential widespread
effect of HDAC inhibition on key processes as cellular
differentiation and development, many of these compounds
are well tolerated in humans and some of them show therapeutic
promise in a wide range of diseases, including cancer, metabolic
and neurological diseases [12,13]. Target specificity and kinetic
properties of HDACIs probably define the spectrum of genes
whose expression they affect, explaining why a catastrophic
general deregulation of gene expression is not observed with
their use.
We found that a commercially available HDACI (BML-210),
and derivatives we have synthesized (pimelic diphenylamides),
relieve repression of the FXN gene in lymphoid cell lines derived
from FRDA patients, in primary lymphocytes from donor FRDA
patient blood, and in the brain and heart of a mouse model for
FRDA [8,9]. Unexpectedly, we also found that only members of
the pimelic diphenylamide family of HDAC inhibitors increase
FXN gene expression, and many common and highly active
HDAC inhibitors, including the hydroxamates trichostatin A
(TSA) and suberoylanilide hydroxamic acid (SAHA), are inactive.
Pimelic diphenylamide HDACIs specifically target class I HDACs,
with the highest inhibitory effect on HDAC3 [14]. They are
further characterized by a slow-on slow-off kinetics, leading to a
more persistent histone hyperacetylation than induced by other
HDACIs, including very potent molecules like suberoylanilide
hydroxamic acid (SAHA).
In an effort to further improve the pharmacological profile of
pimelic diphenylamide HDACIs as potential therapeutics for
FRDA, we synthesized additional compounds with this basic
structure and screened them for HDAC3 specificity. Here we
report the characterization of two of these compounds in FRDA
patients’ peripheral blood lymphocytes and in the KIKI mouse
model. Our results support the development of a therapeutic
approach based on pimelic diphenylamide HDACIs for FRDA
and provide information for the design of future human trials of
these drugs [14].
Results
Two Novel Pimelic Diphenylamides with Histone
Deacetylase Inhibitor Activity




but having a different pattern of HDAC isotype inhibition, were
synthesized: 109: N-(6-(2-aminophenylamino)-6-oxohexyl)-4-methylben-
zamide and 136 N-(6-(2-amino-4-fluorophenylamino)-6-oxohexyl)-4-
methylbenzamide (Figure 1). Purified recombinant HDAC enzymes
were used with a fluorescent substrate to determine IC50 and Ki
values (see Methods S1). The Ki values for HDAC1 and HDAC3,
given as a ratio of HDAC1/HDAC3 are: ,6 fold for 109 and ,3
fold for 136 Figure 1). Both molecules showed the same slow-on/
slow-off inhibition kinetics previously demonstrated for other
compounds of the same class (Figures S1 and S2) [15].
Effects of Compounds 136 and 109 in Unstimulated
Peripheral Blood Mononuclear Cells from FRDA Patients
We tested compounds 136 and 109 for their ability to
upregulate frataxin mRNA in cultures of unstimulated peripheral
blood mononuclear cells (PBMC) obtained from FRDA patients.
Compound 106 (also called RGFA8) that had previously shown
efficacy in this system was used as benchmark positive control.
Compound 136 showed a limited effect in this test (Figure 2A),
even at the highest tested concentration of 10 mM, when
compared to 10 mM compound 106. Frataxin mRNA was not
affected by 136 treatment in PBMC samples P1, P2 and P6, and
was mildly upregulated in samples P3-P5 and P7, whereas
compound 106 increased frataxin mRNA levels by 3.6 fold on
average (p,0.001 in all tested patients with compound 106).
Conversely, compound 109 was highly active in the whole tested
concentration range from 1 to 10 mM (Figure 2B) (p,0.001 in all
Figure 1. Structure and kinetic properties of histone deacetylase inhibitors. The structures of the new compounds 109 and 136 are
shown, along with the structures of the previously described compound 106 [9] and of SAHA. For each compound, the IC50 and Ki for HDAC1 and
HDAC3 are provided.
doi:10.1371/journal.pone.0008825.g001
HDAC Inhibitors in FRDA Models
PLoS ONE | www.plosone.org 2 January 2010 | Volume 5 | Issue 1 | e8825tested patients with compound 109 at 10 mM), showing an almost
linear dose-response relation with the induced frataxin mRNA
increase, except in the case of patient P12. This individual is a late-
onset, mildly affected FRDA patient, who carries relatively short
GAA repeat expansions and has higher baseline frataxin levels
than the other patients, suggesting that HDAC inhibition may be
more effective when long GAA repeat strongly downregulate FXN
expression. Healthy volunteers PBMCs were not overall signifi-
cantly affected by either treatment, though non-significant
fluctuations and a trend toward downregulation by compound
136 were observed (Figure S3). These data are in agreement with
our previous observation that no frataxin upregulation is induced
by compound 106 in the brain and heart of wild-type mice [8].
They indicate that the upregulation of frataxin levels induced by
these compounds in patients’ cells is due to an effect on the
epigenetic changes caused by the expanded GAA repeat.
To follow the duration of effect of 109 in PBMC, cells were
treated with 10 mM 109 or, as a control, with its dimethylsulfoxide
(DMSO)-containing buffer for 24, 48 or 72 hours. Frataxin
mRNA increased to 2.4-fold after 24 hours, 2.7-fold after 48 hours
and 1.8-fold after 72 hours, as revealed by quantitative RT-
PCR (Figure 2D). In a second set of experiments, cells from
patient P13 were treated for 48 hours with 10 mM 109 or
DMSO. A fraction of cells was collected and another fraction
was washed and sub-cultured in regular media without the
HDAC inhibitor for further 6, 12, or 24 hours (Figure 2F).
Frataxin mRNA levels were still stable 6 hours after removing
the drug, they showed an initial decrease at 12 hours and
returned to the pre-treatment baseline 24 hours after drug
removal. The corresponding increase in frataxin protein, as
determined by western blot, occurred more slowly, reaching
,2t o,3.6 fold over baseline (in two separate experiments) at
48 to 72 hours of continuous 109 incubation (Figure 2E and
2G). When the compound was removed after 48 hours of
incubation, frataxin protein levels rapidly increased up to ,6
fold over baseline at 6 hours after the drug washout, and this
marked increase was still present at 24 hours (Figure 2G). The
increase in FXN gene expression was paralleled by increased
histone acetylation, both when determined globally by
estimating the ratio between acetylated and total histone H3,
Figure 2. Effect of compounds 136 and 109 on FRDA patients’ primary lymphocytes. A. FXN mRNA levels were measured in RNA from
isolated PBMCs from patients (P1–P7) after a 48-hour incubation with either 136 or 106 at 10 mM or DMSO (at 0.1%). Quantitative real-time RT-PCR
was used to determine relative FXN levels for each patient condition using GAPDH as a control housekeeping gene. DMSO condition was set to value
1 for each patient. Error is represented as the standard deviation of the mean from 3 determinations. p,0.001 in all tested patients with compound
106. Primary lymphocytes were obtained from donor blood from FRDA patients as described [8]. B. FXN mRNA measurement by quantitative real-
time RT-PCR in RNA from isolated PBMCs from patients (P6–P12) after a 48-hour incubation with 109 at 1, 2.5, 5 or 10 mM, or 106 at 10 mMo ro r136
at 10 mM or with DMSO (at 0.1%) as control. DMSO condition was set to value 1 for each patient, with GAPDH as reference gene. p,0.001 for P6-7
with compound 109 at 5 and 10 mM and with compound 106; p,0.001 in all conditions for P8-P11 except for P11 condition with compound 136;
p,0.001 for P12 only with compound 109 at 10 mM only. C. Representative table of GAA repeat size in tested patients samples. D. PBMCs from
patient P13 were treated with either 109 at 10 mM or DMSO for 24, 48 or 72 hours before harvesting. FXN mRNA was determined by quantitative
real-time RT-PCR, relative to GAPDH. E. Protein extracts were prepared from harvested cells from panel D. treated with DMSO or 109, and subjected
to western blotting with frataxin or GAPDH antibodies. F. Another extraction of PBMC from patient P13 were treated with either 109 at 10 mMo r
DMSO for 48 hours and harvested after a 6, 12 or 24 hours wash out period. FXN mRNA was determined by real-time RT-PCR and in G., frataxin
protein was assessed by western blotting followed by densitometry quantification after the same time points for wash out.
doi:10.1371/journal.pone.0008825.g002
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acetylation of histone H4 at lysine 5 (H4K5) by chromatin
immunoprecipitation (ChIP) (Figure S3).
Effects of Compounds 109 and 136 in KIKI Mice
We previously showed that homozygous knock-in mice carrying
a (GAA)230 repeat in the first intron of the endogenous frataxin
gene (fxn), called KIKI mice [16], recapitulate the genetic and
epigenetic changes observed in FRDA [9]. We injected a group of
KIKI mice (n=5 per group) with a single subcutaneous dose of
150 mg/kg of compound 136 or with an equivalent volume of
vehicle. We sacrificed the mice 24 hours after the injection and
found an increase in frataxin mRNA in the brain to wild-type
levels. To determine the lowest dose of 136 that could achieve a
similar frataxin mRNA increase, we injected KIKI mice with a
single subcutaneous dose of 5, 15, 50 or 150 mg/kg of compound
136 (n=6 or 7 per group) or with vehicle (n=13). Fxn mRNA
significantly increased in the brain (p,0.001) and in the heart
(p=0.009 and 0.008 respectively) only in mice that received 50 or
150 mg/kg (Figure 3A). In the brains of mice from these groups,
we observed by chromatin immunoprecipitation (ChIP) an
increase in histone acetylation at positions H3K14 and H4K5 in
the region of the fxn gene immediately upstream of the inserted
GAA repeat (Fig. 3B).
Compound 109 was also able to correct frataxin deficiency in
the brain and heart of KIKI mice 24 hours after a single
injection of a 150 mg/kg dose, but not when lower doses were
used (data not shown). When followed in time, the frataxin
mRNA increase induced by compound 109 in the KIKI mouse
could be first detected at 12 hours (n=4) and reached a
maximum at 24 hours (n=9) in both brain (p,0.001) and heart
(p=0.02) (Figure 4A). Frataxin mRNA levels then showed a
decrease at 48 hours and returned to normal levels by 72 hours.
The frataxin protein similarly increased at 24 hours and
returned to baseline at 72 hours (data not shown). Histone
acetylation of residues H3K14 and H4K5 in the region
upstream of the GAA repeat, as revealed by ChIP, also
increased between 12 and 24 hours after the HDACI injection
(Figure 4B). In order to compare this effect on histone
acetylation near the GAA repeat with the overall effect of the
compound on histone acetylation, we injected a group of wild-
type mice (n=5 per time point) with either vehicle or 109 at
150 mg/kg and estimated total and acetylated histone H3 levels
in brain by western blot (Figure 4C). Acetylation increased to a
maximum level at 4 hours after injection and totally disap-
peared at 24 hours. Finally, we determined the levels of
compound 109 in the mouse brain and plasma after a single
150 mg/Kg injection and found out that it is totally eliminated
before 4 hours (Figure 4D). No acute toxicity signs such as
changes in respiration, activity, temperature or lack of sedation
were noticed in any of the above experiments, as observed in the
open cage behavior.
Because of the discrepancy between patients’ PBMCs and KIKI
mouse tissues in the relative response to compounds 109 and 136,
we compared the effect of HDACi 106, 109 and 136 in
splenocytes collected from pooled KIKI or WT mice spleens.
Splenocytes are close to PBMCs in terms of cell type composition,
both being mostly lymphocytes, allowing to test whether the
different response in human vs. mouse was due to a species
difference or to a different relative sensitivity to the HDACIs of the
tested cell types, mostly lymphocytes in humans vs. central nervous
system and heart cells in the mouse. In mouse splenocytes, frataxin
mRNA upregulation was significant (p,0.001) only with com-
pounds 106 and 136 (Figure 5), supporting a species difference.
Discussion
We generated new pimelic diphenylamide HDACIs to maxi-
mize efficacy in upregulating frataxin and to optimize pharmaco-
logical properties in view of a future translation to the clinic. The
new compounds show the same type of inhibition kinetics and
HDAC3 specificity as the previously reported molecules. We
selected two of these compounds, 109 and 136, that differ for
Figure 3. Frataxin expression changes as function of drug 136
dosage. A. Fxn mRNA measurement by quantitative real-time RT-PCR
in brain and heart of KIKI mice dosed subcutaneously with 136 at 5
(n=7), 15 (n=7), 50 (n=6) or 150 (n=6) mg/kg or vehicle (n=13) as
negative control. Fxn levels were relative to RER1 and beta-2
microglobulin (b2M). The Fxn level in vehicle injected KIKI of each
tissue was set to 100. All quantifications were done in triplicate and bars
indicate s.d. (** p,0.001; * p,0.05). B. Levels of H4K5 and H3K14
acetylation in KIKI mice brain treated with one subcutaneous injection
of 50 or 150 mg/kg of 136 compared to vehicle-treated KIKI littermates
(n=4). We performed ChIP experiments with antibodies for murine
histones H3 and H4 carrying each modification. Primer pairs corre-
sponded to the first intron of the mouse frataxin gene just upstream of
the point of insertion of the GAA repeat in KIKI mice. Relative recovery,
determined by qPCR, is expressed in relation to GAPDH and the
recovery in samples from vehicle treated KIKI animals is set to 100 for
each antibody. Each immunoprecipitation was quantified in triplicate,
Error bars are s.e.m.
doi:10.1371/journal.pone.0008825.g003
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higher for compound 109 (Figure 1), and tested them in FRDA
patients’ PBMC and in the KIKI mouse model. We then
determined in both systems the duration of effect of these drugs
on frataxin mRNA and protein, and on total and local (upstream
of the GAA repeat) histone acetylation.
In FRDA patients’ PBMC, compound 109 was much more
potent than compound 136 in upregulating frataxin, supporting
the concept that HDAC3 selectivity correlates with this
property. A good dose-response correlation could be detected
for compound 109, with a 4- to 9-fold upregulation of frataxin
mRNA at the highest tested concentration of 10 mM. Rather
surprisingly, however, compound 136 turned out to be effective
at a threefold lower dose and more consistently in the KIKI
mouse model, both in the FRDA target tissues after sub-
cutaneous treatment and in in vitro treated splenocytes. At this
time we have no definite explanation for such a discrepancy.
The similar response of mouse splenocytes (closely related to the
PBMCs tested in human patients) and of mouse nervous and
cardiac tissue supports the hypothesis of a species difference
rather than a cell type difference. It is possible that the mouse
and human enzymes have differences in the response to the
Figure 4. Time course for drug exposure, frataxin mRNA expression, and histone acetylation changes in the brain and heart of
KIKI mice. A. Fxn mRNA measurement by quantitative real-time RT-PCR in brain and heart of KIKI mice dosed subcutaneously with 109 at
150 mg/kg (n=26) or vehicle (n=13). Treated mice were sacrificed at one of the mentioned time points: 4, 12, 24, 48 or 72 h. Vehicle treated
mice were sacrificed 24 hours after injection. Fxn mRNA levels were relative to RER1 and beta-2 microglobulin (b2M). The Fxn level in vehicle
injected KIKI of each tissue was set to 100. All quantifications were done in triplicate and bars indicate s.d. (** p,0.001; * p,0.05). B. Levels of
H4K5 and H3K14 acetylation in KIKI mice brain treated with one subcutaneous injection of 150 mg/kg of 109 compared to vehicle-treated KIKI
littermates, after 4, 12, 24 or 48 hours (n=4 for each shown time point). We performed ChIP experiments with antibodies for murine histones H3
and H4 carrying each modification. Primer pairs corresponded to the first intron of the mouse frataxin gene just upstream of the point of
insertion of the GAA repeat in KIKI mice. Relative recovery, determ i n e da sp r e v i o u s l y( F i g .3 B )i ss e tt o1 0 0f o re a c hr e s i d u e .E a c h
immunoprecipitation was quantified in triplicate. Error bars are s.e.m. C. Brains from wild-type mice for total histone H3 acetylation and from
KIKI mice for specific residues acetylation, injected with either vehicle or with 150 mg/kg of 109, were harvested after a period of 1, 4, 12, 24, 48
or 72 hours (n=5 per condition) and subjected to western blot with total or acetylated histones H3 antibodies for WT samples or to chromatin
immunoprecipitation for KIKI samples. Ratio of acetylated H3 over total H3 is plotted, showing a peak of acetylation at 4 hours. Recovery of
specific residues is plotted, showing a plateau between 12 and 24 hours. D. Composite graphic of 109 measures in mouse brain: in black, drug
109 exposure measured in mg/ml; in blue, total histone acetylation from western blot quantification (panel C); in red, fxn RNA as determined by
qPCR in panel A.
doi:10.1371/journal.pone.0008825.g004
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the human enzyme. It is also possible that the compounds differ
in pharmacokinetic or metabolic properties in the mouse. Such
species differences have to be taken into account in the
preclinical development of these drugs.
An important conclusion of thiss t u d yc o m e sf r o mt h ea n a l y s i s
of the time course of the effects of these compounds in patients’
PBMC and in mice, that long exceeds the time of direct
exposure to the drugs. Frataxin mRNA remained elevated in
PBMC for at least 12 hours after drug removal and in mice for
at least 24 hours after a single subcutaneous injection. In both
systems, the time course of frataxin mRNA upregulation
paralleled the increase in total and local histone acetylation.
These data confirm that HDAC inhibition is a more persistent
phenomenon after transient exposure to this category of
compounds than to other HDACIs like SAHA [15]. Most
importantly, the increase in frataxin protein was the most
sustained effect, lasting more than 48 hours after drug dosing in
the mouse. It is of note that frataxin protein levels sharply
increased in PBMC immediately after drug washout, reaching
much higher levels compared to those obtained with continued
exposure to the compounds. This finding may be due to
inhibition of translation or of some post-transcription RNA
processing step by the HDACI [17]. Taken together, these data
suggest that intermittent administration of the drug, i.e. less
than once daily and possibly as spaced as once or twice a week,
may be the dosing regime of choice for the future clinical testing
of these drugs. Such regimen would minimize toxic side effects
by reducing drug exposure, at the same time allowing sustained
upregulation of frataxin protein.
Finally, it is important that this class of HDACIs has not shown
any apparent toxicity in this series of experiments, neither in cell
culture, nor in the animal studies. These studies were not designed
to provide a complete assessment of acute toxicity, however, and
complete preclinical testing will be necessary before any human
test. Together with the previous studies [8,9], the present results
support the pre-clinical development of pimelic diphenylamide
HDACIs as potential therapeutics for FRDA.
Methods
Ethics Statement
Friedreich’s ataxia patients donated blood (Human Subjects
Protocol approved by the Erasme Hospital ethics committee) with
appropriate written informed consent. All animal procedures
respected regulations and guidelines of the Belgian state and
European Union and were approved by the local ethical
committee (CEBEA).
Animal Procedures
GAA knock-in mice were generated and genotyped as
described[16]. Age and gender matched WT littermates were
used as controls. Mice were treated by a single subcutaneous
injection with 150 mg/kg (or other dose when mentioned) of
HDACi 109 or HDACi 136 or its equivalent of vehicle. Brain and
heart were recovered 24 hours after last injection, or at indicated
time.
Primary Lymphocytes Culture
About 40 ml of blood was collected in heparinized Vacutainer
tunes (BD Biosciences) and lymphocytes were isolated by density
centrifugation using Ficoll – Paque PLUS (GE Healthcare),
according to the manufacturer. Lymphoctyes were maintained
in RPMI 1640 medium with 2 mM l-glutamine, penicillin /
streptomycin and 15% FBS at 37uCi n5 %C O 2. Cells viability
and morphology were monitored by trypan blue exclusion on
phase-contrast microscopy. We dissolved compounds 106, 136
and 109 in DMSO and added the solution into the culture
medium at the concentrations and for the duration indicated in
Figure 2. Controls were treated with the same concentration of
DMSO-lacking compounds.
Mouse Splenocytes Culture
Spleens collected from KIKI or WT mice were mashed between
2 glass slides, ground with a 1-mL syringe pestle, then suspended
in RPMI 1640 medium supplemented with 2 mM l-glutamine,
15% fetal calf serum and penicillin / streptomycin before filtering
through a 75-mm nylon mesh. After washes, red blood cells were
removed with lysis buffer (155 mM NH4Cl (pH 7.4), 10 mM
NaHCO3, 0.1 mM EDTA). Spleen mononuclear cells were
collected, washed, and resuspended before subculturing in
triplicate for 48 hours in culture medium containing DMSO
(negative control (-)) or one of HDACi 106, 109 and 136 at
10 mM.
Quantitative Real Time PCR
Total RNA was extracted from PBMC and splenocytes by
RNeasy Mini Kit (Qiagen). Total RNA from mice brain was
extracted by RNeasy Lipid Tissue Mini Kit (Qiagen) as
recommended by the manufacturer. RNA from mice heart was
extracted by RNeasy Fibrous Tissue Mini Kit (Qiagen). All RNA
samples were treated with RNase-Free DNase Set (Qiagen) and
quantified afterwards by measuring the optical density (NanoDrop
ND-1000 Spectrophotometer, NanoDrop Technologies). Quality
and purity of some samples were analyzed by gel electrophoresis
on RNA assay chips (Experion System and StdSens analysis kit,
BioRad Laboratories). We performed one-step qRT-PCR using
MultiScribe Reverse Transcriptase with Power SYBR Green (both
from Applied Biosystems). Primers used for FXN were 59-
CAGAGGAAACGCTGGACTCT-39 and 59-AGCCAGATTT-
GCCTTGTTTGG-39, and primers for Fxn were 59- CCTG-
GCCGAGTTCTTTGAAG-39 and 59- GCCAGATTTGCTTG-
TTTGG-39. Cells RNA was standardized by quantification of
Figure 5. Effect of compounds 106, 109 and 136 in unstimu-
lated KIKI splenocytes. Splenocytes were collected from pooled KIKI
spleens (n=3) or WT spleens. Spleen mononuclear cells were cultured
in triplicate for 48 hours with one of HDACi 106, 109 and 136 at
10 mM or with DMSO for KIKI samples. WT samples were cultured in
triplicate for 48 hours with. Quantitative real-time RT-PCR was used to
determine relative Fxn levels for each condition using RER1 and b2M as
control housekeeping genes. DMSO KIKI condition was set to value 1.
Error is represented as the standard deviation of the mean from 3
determinations. p,0.001 for 106 and 136 KIKI responses.
doi:10.1371/journal.pone.0008825.g005
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RER1 and beta-2 microglobulin (b2M) using qBase 1.3.4 (Jan
Hellemans & Jo Vandesompele). These control genes were chosen
because they did not show genotype (KIKI vs. wild-type) or
treatment-related changes. Data are normalized to the fxn mRNA
level in vehicle treated KIKI (=100%) or to the FXN (or Fxn)
RNA level in DMSO treated cells (=1).
Western Blot Analysis
Tissues were homogenized in T-PER tissue protein extraction
reagent (Pierce) for total proteins extraction. Histones were
purified by acid extraction as described in the protocols from
Upstate. Primary antibodies were diluted in Odyssey blocking
buffer (Li-Cor) for frataxin (Chemicon) and actin (Sigma) or in
PBS for total and acetylated histones antibodies (Upstate) and for
human frataxin (Mitosciences). Infrared dye conjugated secondary
antibodies (anti-rabbit IRdye800Cw and anti-mouse IRdye680
from Li-Cor) were used to detect and quantify the signal of mouse
frataxin / actin using a Li-Cor Odyssey imaging system.
Horseradish Peroxidase (HRP) - conjugated secondary antibodies
(Santa Cruz Biotechnology) were used to detect the signal of total
and acetylated histones and for the human frataxin / Gapdh signal
by chemiluminescence.
Chromatin Immunoprecipitation
ChIP was performed as described previously[20]. We adapted
the technique for use on fresh brain tissue and were able to test 3
different residues per one hemisphere. For each immunoprecip-
itation, lysate was incubated with one of the following antibodies
(Anti-acetyl-Histone H3 (Lys14): Upstate Biotechnology 07-353;
Anti-acetyl-Histone H4 (Lys5): Upstate 07-327; Normal Rabbit
IgG: Upstate 12-370). Immunoprecipitated samples were quanti-
fied by real-time PCR following the standard curve method.
Primers used for the region upstream intronic GAA repeats of Fxn
were 59- ACGACAAAGTCTCCCACAGG-39 and 59- GTCCA-




Data are presented as mean 6 s.d. or s.e.m., or as percentages.
The significance of the difference between groups was evaluated
with the Student’s t-test or one-way ANOVA. p,0.05 was
considered significant. (*p,0.05 unless otherwise noted).
Supporting Information
Figure S1 Compound 136 IC50 determination for HDAC1 and
HDAC3/NcoR2 (left panel, top/bottom). Compound 136 shows a
time-dependent inhibition of HDAC3/NcoR2. IC50s against
HDAC3/NcoR2 decrease from 16.8 mM to 560 nM over a period
of 3 hours. There is no time-dependent inhibition of HDAC1 with
compound 136. Compound 136 is a fast on/off inhibitor of
HDAC1 with Ki at 630 nM (right panel, top). Compound 136,
however, is a slow-tight binding inhibitor of HDAC3/NcoR2 with
Ki at 196 nM (right panel, bottom).
Found at: doi:10.1371/journal.pone.0008825.s001 (2.63 MB TIF)
Figure S2 Inhibitor 109 IC50s determination for HDAC1 and
HDAC3/NcoR2 (left panel, top/bottom). Inhibitor 109 shows a
time-dependent inhibition for both HDAC1 and HDAC3/
NcoR2. Its IC50s against HDAC1 decrease from 230 nM to
60 nM within an hour. Inhibitor 109 IC50s against HDAC3/
NcoR2 decrease from 1 mMt o5 0n Mo v e rap e r i o do f3h o u r s .
109 are slow-tight binding inhibitor of both HDAC1 and
HDAC3/NcoR2, but the on rate of 109 is faster for HDAC1
than for HDAC3/NcoR2. Compound 109 has a Ki of 32 nM
(right panel, top) for HDAC1 and a Ki of 5 nM for HDAC3/
NcoR2 (right panel, bottom).
Found at: doi:10.1371/journal.pone.0008825.s002 (2.21 MB TIF)
Figure S3 Upper panel: Effect of compounds 106, 109 and 136
on PBMCs from subjects with normal GAA repeats (healthy
volunteers). FXN mRNA levels were measured after a 48-hour
incubation with either 106, 109 and 136 at 10 mM or DMSO (at
0.1%). Quantitative real-time RT-PCR was used to determine
relative FXN mRNA levels for each individual condition using
GAPDH as control housekeeping gene. DMSO condition was set
to value 1 for each individual. Error is represented as the standard
deviation of the mean from three dterminations. PBMCs were
obtained from donors’ blood as described [8]. Middle and lower
panels: Changes in local and global acetylation upon removal of
HDACi 109. PBMCs from patient P13 were treated with either
DMSO or 109 for 48 hours and part of these two samples were
collected (samples ‘‘DMSO’’ and ‘‘0h’’), and the rest washed to
remove the inhibitor. Samples were then collected at 6, 12, 24 and
48 hours after washing. At each time point, we measured FXN
mRNA levels (upper left panel), occupancy of H4AcK5 on the
frataxin gene, upstream of the GAA repeats (upper right panel)
and global H3 acetylation (lower left panel, quantified in the lower
left panel).
Found at: doi:10.1371/journal.pone.0008825.s003 (2.55 MB TIF)
Methods S1 Supplementary Methods.
Found at: doi:10.1371/journal.pone.0008825.s004 (0.04 MB
DOC)
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